The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...
Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.
Background: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is no evidence from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results